Pre and Post Hospitalization Resource Utilization and Costs Associated with Urinary Tract Infection (UTI) in both Commercial and Medicare Populations Posted on October 27, 2020 at 3:42 pm.Written by Spero Therapeutics View Presentation Post navigation Hospital Costs and Reimbursement in Patients with Resistant Enterobacteriaceae (ENT) Urinary Tract Infection (UTI) in the United States (US): A Multicenter AnalysisPhase 1 First-in-Human Single-and Multiple-Ascending Dose Trial Demonstrates Pharmacokinetics and Tolerability of SPR720, an Oral DNA GyrB Inhibitor for Mycobacterial Infections
